Dernières nouvelles pour Addus HomeCare (NASDAQ:ADUS) Stock

Addus HomeCare

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

Addus HomeCare Corporation - Common Stock

Addus HomeCare Corp

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $142.67, along with a high estimate of $150.00 and a low estimate of $136.00. This upward trend is apparent, with the current average reflecting a 1.33% increase from the previous average price target of $140.80.
<img src="https://www.benzinga.com/files/images/story/2025/1737748878_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Addus HomeCare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ari Wald</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$136.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$136.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Addus HomeCare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Addus HomeCare analyst ratings.</a>
<h2>Delving into Addus HomeCare's Background</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Understanding the Numbers: Addus HomeCare's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Addus HomeCare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Addus HomeCare's net margin excels beyond industry benchmarks, reaching 6.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Addus HomeCare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.16%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Addus HomeCare's ROA excels beyond industry benchmarks, reaching 1.78%. This signifies efficient management of assets and strong financial health.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ADUS

Deep Dive Into Addus HomeCare Stock: Analyst Perspectives (6 Ratings)

Oppenheimer analyst Ari Wald maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and raises the price target from $145 to $150.

News

Price Target

Oppenheimer Maintains Outperform on Addus HomeCare, Raises Price Target to $150

WIIM

Addus HomeCare shares are trading higher. JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $150.

JMP Securities initiated coverage on Addus HomeCare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), a provider of home-based personal care and clinical services.
JMP analysts see Addus HomeCare as having a uniquely strong and well-established presence in personal care services across multiple states, thanks to the company's scale and experienced management team.
The analyst writes that personal care is a cost-effective way to provide home-based services, especially as the U.S. faces a shortage of expensive skilled clinicians.
This approach also helps delay the need for more costly care options. With the highly fragmented personal care sector, Addus has opportunities to expand by adding complementary home health and hospice services to its existing markets.
The analysts expect this strategy to support sustained double-digit revenue growth for the company in the coming years.
In the third quarter, Addus HomeCare revenues were $289.8 million for the third quarter of 2024, a 7.0% increase compared with $270.7 million for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41727154/addus-homecare-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">the third quarter of 2023</a>.
JMP has initiated with a price target of $150, with <a target="_blank" href="https://www.benzinga.com/quote/ADUS/analyst-ratings" rel="noreferrer noopener">a Market Perform rating</a>.
Addus HomeCare recently acquired Gentiva's PC operations. The deal, the largest acquisition in the company's history, is expected to allow Addus HomeCare to enter Texas with critical mass and add personal care services in six other states, three of which are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42276478/addus-homecare-completes-acquisition-of-personal-care-operations-of-gentiva" rel="noreferrer noopener">new to the company</a>.
Gentiva's PC platform is expected to contribute annual revenue of $275 million-$280 million, prompting 29% year-over-year personal care growth for Addus HomeCare in 2025, above the segment's five-year CAGR (2019-2024E) of 8%.
JMP writes that in recent years, Addus HomeCare has expanded into value-based care (VBC) arrangements in select markets through its "Care Advantage" program.
The company is well-positioned to grow in this area thanks to its combination of clinical and non-clinical care resources, along with its large-scale operations and robust case management systems.
Price Action: ADUS stock is up 5.14% at $131.42 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/24/12/42505835/honeywell-advances-strategic-review-explores-aerospace-business-separation" target="_blank" rel="noreferrer noopener">Honeywell Advances Strategic Review, Explores Aerospace Business Separation</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Health Care

Initiation

Movers

Trading Ideas

General

As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Eric Sheridan initiated coverage on Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Buy rating and announced a price target of $20. Grindr shares closed at $15.74 on Friday. See how other analysts view this stock.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on Addus HomeCare Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform rating and announced a price target of $150. Addus HomeCare shares closed at $125.00 on Friday. <a href="https://www.benzinga.com/quote/ADUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Matthew Caufield initiated coverage on Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Buy rating and announced a price target of $30. Zenas BioPharma shares closed at $8.92 on Friday. <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Market Outperform rating and announced a price target of $113. US Physical Therapy shares closed at $93.46 on Friday. See how other analysts view this stock.</li>
<li>Jones Trading analyst Justin Walsh initiated coverage on Alto Neuroscience, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) with a Buy rating and announced a price target of $18. Alto Neuroscience shares closed at $3.83 on Friday. <a href="https://www.benzinga.com/quote/ANRO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADUS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png" alt="" class="wp-image-693734" style="width:595px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields

Pre-Market Outlook

Markets

ANRO

GRND

USPH

ZBIO

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

JMP Securities analyst Constantine Davides initiates coverage on Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform rating and announces Price Target of $150.

JMP Securities Initiates Coverage On Addus HomeCare with Market Outperform Rating, Announces Price Target of $150

RBC Capital analyst Ben Hendrix reiterates Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and maintains $136 price target.

Reiteration

RBC Capital Reiterates Outperform on Addus HomeCare, Maintains $136 Price Target

Stephens &amp; Co. analyst Scott Fidel maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Overweight and raises the price target from $143 to $145.

Stephens & Co. Maintains Overweight on Addus HomeCare, Raises Price Target to $145

RBC Capital analyst Ben Hendrix maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and lowers the price target from $141 to $136.

RBC Capital Maintains Outperform on Addus HomeCare, Lowers Price Target to $136

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.28 by 1.56 percent. The company reported quarterly sales of $289.90 million which beat the analyst consensus estimate of $289.39 million by 0.17 percent. This is a 7.08 percent increase over sales of $270.72 million the same period last year.

Earnings

Earnings Beats

Addus HomeCare Q3 2024 Adj EPS $1.30 Beats $1.28 Estimate, Sales $289.90M Beat $289.39M Estimate

Across the recent three months, 9 analysts have shared their insights on Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $141.67, with a high estimate of $150.00 and a low estimate of $137.00. Surpassing the previous average price target of $135.50, the current average has increased by 4.55%.
<img src="https://www.benzinga.com/files/images/story/2024/1730750434_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Addus HomeCare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Addus HomeCare's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Addus HomeCare analyst ratings.</a>
<h2>Delving into Addus HomeCare's Background</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Addus HomeCare: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Addus HomeCare's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Addus HomeCare's net margin excels beyond industry benchmarks, reaching 6.3%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Addus HomeCare's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.2%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.7%, the company showcases effective utilization of assets.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Addus HomeCare: Insights From 9 Financial Analysts

Macquarie analyst Tao Qiu maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and maintains $139 price target.

Macquarie Maintains Outperform on Addus HomeCare, Maintains $139 Price Target

9 analysts have shared their evaluations of Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $141.56, with a high estimate of $150.00 and a low estimate of $137.00. This upward trend is evident, with the current average reflecting a 4.56% increase from the previous average price target of $135.38.
<img src="https://www.benzinga.com/files/images/story/2024/1728669610_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Addus HomeCare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Addus HomeCare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Addus HomeCare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Addus HomeCare analyst ratings.</a>
<h2>Get to Know Addus HomeCare Better</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Addus HomeCare: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Addus HomeCare's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Addus HomeCare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.3%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.2%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Addus HomeCare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.7% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Addus HomeCare In The Eyes Of 9 Experts

Keybanc analyst Matthew Gillmor initiates coverage on Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Overweight rating and announces Price Target of $150.

Keybanc Initiates Coverage On Addus HomeCare with Overweight Rating, Announces Price Target of $150

8 analysts have expressed a variety of opinions on Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Addus HomeCare, presenting an average target of $140.12, a high estimate of $145.00, and a low estimate of $136.00. This upward trend is apparent, with the current average reflecting a 3.9% increase from the previous average price target of $134.86.
<img src="https://www.benzinga.com/files/images/story/2024/1727100016_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Addus HomeCare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$136.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Addus HomeCare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Addus HomeCare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Addus HomeCare analyst ratings.</a>
<h2>Get to Know Addus HomeCare Better</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Addus HomeCare's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Addus HomeCare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.36% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Addus HomeCare's net margin excels beyond industry benchmarks, reaching 6.3%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Addus HomeCare's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.2%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.7%, the company showcases effective utilization of assets.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average. With a ratio of 0.05, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Addus HomeCare: Insights From 8 Analyst Reviews

Oppenheimer analyst Michael Wiederhorn maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and raises the price target from $140 to $145.

Oppenheimer Maintains Outperform on Addus HomeCare, Raises Price Target to $145

W. Bradley Bickham, President and COO at Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), reported an insider sell on September 3, according to a new SEC filing. 
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001468328/000095017024102849//Archives/edgar/data/1468328/000095017024102849/0000950170-24-102849-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that Bickham executed a sale of 5,000 shares of Addus HomeCare with a total value of $660,912.
As of Wednesday morning, Addus HomeCare shares are down by 0.0%, currently priced at $130.01.
<h3>Get to Know Addus HomeCare Better</h3>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Addus HomeCare's Economic Impact: An Analysis</h3>
Revenue Growth: Addus HomeCare's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 32.47%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Addus HomeCare's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.12.
</li>
</ul>
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 30.96 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 1.91 is lower than the industry average, implying a discounted valuation for Addus HomeCare's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Addus HomeCare's EV/EBITDA ratio, lower than industry averages at 19.09, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001468328">Check Out The Full List Of Addus HomeCare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Addus HomeCare President and COO Sold $660K In Company Stock

Across the recent three months, 9 analysts have shared their insights on Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Addus HomeCare, revealing an average target of $137.11, a high estimate of $143.00, and a low estimate of $128.00. Marking an increase of 5.37%, the current average surpasses the previous average price target of $130.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1725372037_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Addus HomeCare by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$136.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$128.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$118.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Addus HomeCare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Addus HomeCare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Addus HomeCare analyst ratings.</a>
<h2>Delving into Addus HomeCare's Background</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Addus HomeCare: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Addus HomeCare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.36% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Addus HomeCare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.3%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Addus HomeCare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Addus HomeCare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.7% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Addus HomeCare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Addus HomeCare

RBC Capital analyst Ben Hendrix reiterates Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and maintains $141 price target.

RBC Capital Reiterates Outperform on Addus HomeCare, Maintains $141 Price Target

Press Releases

Addus HomeCare Announces Proposed Public Offering of Common Stock

Addus HomeCare Announces Pricing of Public Offering of Common Stock

Addus HomeCare Announces Closing of Public Offering

Addus HomeCare Announces Second Quarter 2024 Earnings Release and Conference Call

Addus HomeCare Announces Second Quarter 2024 Financial Results

Addus HomeCare Announces Third Quarter 2024 Earnings Release and Conference Call

Addus HomeCare Announces Third Quarter 2024 Financial Results

Addus HomeCare to Participate in Stephens Annual Investment Conference

Addus HomeCare Completes Acquisition of Personal Care Operations of Gentiva

Addus HomeCare Announces Fourth Quarter and Year-end 2024 Earnings Release and Conference Call

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Addus HomeCare

Actualités

Dernières nouvelles pour Addus HomeCare (NASDAQ:ADUS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL